Medicine by Alexandros G. Sfakianakis: High-Dose Omalizumab versus Ligelizumab for the Treatment of Chronic Spontaneous Urticaria: Do Not We Need a Head-To-Head Comparison?

Πέμπτη 17 Δεκεμβρίου 2020

High-Dose Omalizumab versus Ligelizumab for the Treatment of Chronic Spontaneous Urticaria: Do Not We Need a Head-To-Head Comparison?

Alexandros G.Sfakianakis shared this article with you from Inoreader

High-Dose Omalizumab versus Ligelizumab for the Treatment of Chronic Spontaneous Urticaria: Do Not We Need a Head-To-Head Comparison?

Μέσω IAA : Last 20 articles

?image=000512373-1.jpg

Int Arch Allergy Immunol

View on the web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Εγγραφή σε: Σχόλια ανάρτησης (Atom)